Company news
Cybin, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update
July 8, 2024
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023
November 1, 2023
Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023
October 31, 2023
Cybin to Acquire Small Pharma Inc.
August 28, 2023
Cybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programs
August 21, 2023
Trippy Trading: Top Psychedelic Stocks For 2023
January 17, 2023
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
October 18, 2021
Decks
- Investor Presentation (August 2026)
Investor deck · 45 slides · August 2026
- Helus Pharma — Technical Presentation (March 2026)
Technical · 20 slides · Mar 5, 2026
- Q2 2026 Earnings Presentation
Earnings · 30 slides · Nov 13, 2025